Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Inogen, Inc.NASDAQ: INGN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows in line with its trailing trend
Q1 FY2026 revenue of $85.11M rose 3.4% year over year, in line with the +3.4% change in trailing-twelve-month revenue. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $311.3M (-10.7%) for the fiscal year ending Dec 2026, a slowdown from the +3.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $85.11M+4.1% QoQ
- Last fiscal yearDec 2025
- $348.67M+3.9% YoY
- LTMMar 2026
- $351.5M+3.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.4% | +3.2% | -0.2 pp |
| 1 year | +3.9% | -10.7% | -14.6 pp |
| 3-year CAGR | -2.6% | -1.9% | +0.7 pp |
| 5-year CAGR | +6.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 348.67M USD
- Year-over-year change
- +3.9%
- 4-year CAGR
- -0.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 348.67M | +3.9% |
| FY2024 | 2024-12-31 | 335.71M | +6.4% |
| FY2023 | 2023-12-31 | 315.66M | -16.3% |
| FY2022 | 2022-12-31 | 377.24M | +5.4% |
| FY2021 | 2021-12-31 | 358M | — |
Revenue vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 revenue of $351.5M is the highest of the 11 companies compared; the peer median is $49.11M.
- Its year-over-year change of +3.4% is the 6th highest of 10, against a peer median of +8.2%.
- Over three fiscal years its annual growth of -2.6% compares with a peer median of +6.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $351.5M | +3.4% | -2.6% | |
| LTM Mar 2026 | $302.48M | -2.8% | +4.0% | |
| LTM Mar 2026 | $144.87M | +8.2% | +9.5% | |
| LTM Mar 2026 | $117.59M | +2.0% | +1.2% | |
| LTM Mar 2026 | $79.55M | +1.8% | +2.7% | |
| LTM Mar 2026 | $53.89M | +55.9% | — | |
| LTM Mar 2026 | $44.33M | +22.5% | +38.1% | |
| LTM Dec 2025 | $13.02M | +15.4% | +14.9% | |
| LTM Mar 2026 | $9.59M | +2109.4% | +97.0% | |
| LTM Mar 2026 | $618K | -58.0% | -50.1% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding INGN) | $49.11M | +8.2% | +6.8% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 358M | 377.24M | 315.66M | 335.71M | 348.67M |
| Cost of Revenue | 181.52M | 223.71M | 188.96M | 180.96M | 182.78M |
| Gross Profit | 176.48M | 153.53M | 126.7M | 154.74M | 165.89M |
| Gross Margin | 49.3% | 40.7% | 40.1% | 46.1% | 47.6% |
| Research & Development | 16.58M | 21.94M | 20.84M | 21.61M | 19.4M |
| Selling, General & Admin | 150.67M | 164.67M | 182.35M | 175.65M | 165.07M |
| Operating Expenses | 167.24M | 238.78M | 236.09M | 197.26M | 196.1M |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| EBITDA | 30.29M | (9.57M) | (58.34M) | (15.47M) | (2.72M) |
| EBITDA Margin | 8.5% | -2.5% | -18.5% | -4.6% | -0.8% |
| Operating Income | 9.24M | (85.24M) | (109.39M) | (42.52M) | (30.21M) |
| Operating Margin | 2.6% | -22.6% | -34.7% | -12.7% | -8.7% |
| Interest Income | 129K | 2.84M | 6.57M | 5.19M | 2.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (581K) | 1.98M | 7.04M | 6.04M | 6.83M |
| Income Before Tax | 8.66M | (83.27M) | (102.34M) | (36.48M) | (23.38M) |
| Pre-Tax Margin | 2.4% | -22.1% | -32.4% | -10.9% | -6.7% |
| Income Tax Expense | 14.99M | 504K | 105K | (588K) | (632K) |
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Net Margin | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% |
| EPS (Basic) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| EPS (Diluted) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| Weighted Avg Shares | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
| Weighted Avg Shares (Diluted) | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.